Hints and tips:
Related Special Reports
Related Topics
...The company is aiming to develop a wide range of drugs and use its manufacturing scale to stay ahead of pharmaceutical rivals seeking to profit from consumer “hype” for weight loss products, he added....
...Zealand’s products in development will have to compete with the popular Wegovy and Zepbound drugs already on the market and made by Novo Nordisk and Eli Lilly respectively, which suppress appetite....
...AstraZeneca is a specialist in cancer treatments, making $17bn and 37 per cent of sales from oncology products in 2023....
...Novavax is this year rolling out its second product: a malaria vaccine approved by the World Health Organization, which will help to grow its revenues from $531.4mn last year to a projected $854.2mn this...
...Jeff Emmick, Eli Lilly’s senior vice-president of product development, said that while as many as 80mn US adults may suffer from obstructive sleep apnoea, about a quarter of whom face more serious symptoms...
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
...It represents a major increase in power for Hassabis, who joined Google when it bought his start-up in 2014, and who now controls much of its AI development and product output....
...“It will encourage them to make sure the medicines are available here and it’s a route for people to get tested with the new medicines in development.”...
...Daiichi Sankyo, which developed the drug with AstraZeneca and leads on marketing of the product in the UK, said it was “extremely disappointed by the decision”....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...Pharmaceutical companies must replenish their drugs pipeline before exclusivity rights on top-selling products expire....
...Pharmaceutical companies also have a key role to play in providing affordable access to these essential products. The global industry’s response to date has been inadequate and fragmented....
...“But the elegant synthetic design of cresomycin, based on an intuitive rationale, provides an exciting scaffold for further development.”...
...make up the backbone of pharmaceutical care....
...The global contract development and manufacturing market, which supports pharma companies in making products and running clinical trials, is projected to grow from $72bn to $90bn over the next two years,...
...But Eli Lilly declined to say how much of the product would be available in Britain, or which pharmacies will stock the product. Patients in Northern Ireland will not have access to the pen....
...But she said believed new entrants would be able to break into the market “if the product is sufficiently differentiated”....
...Lex has been watching the development of this market closely....
...Zealand expects 10 per cent royalties from any eventual sales of the product....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...“The issue affects anyone developing antifungal drugs because regulatory requirements make the development time for human medicines much longer than for agricultural chemicals,” said Birch....
...The idea of so-called molecular factories harnesses the basic machinery of sustaining life, in which cells constantly turn out biochemical products....
...Drugs made by Japan’s Eisai and Eli Lilly of the US have shown promise when used early in an individual’s development of the disease....
...shares tumbled more than 8 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid-19 products...
...Despite having a product on the market and being identified by analysts as a potential acquisition target for several large pharmaceutical companies, many European shareholders are still reluctant to invest...
International Edition